Figures & data
Table 1 Overview of the 19 centers in the six Italian regions participating in the study
Figure 1 The theoretical model to analyze the subcutaneous versus intravenous therapy benefits in Italy.
Notes: I admin, first administration; II + admin, administration of therapy second and further times.
Table 2 Size differences in participating centers
Table 3 Time difference in patient preparation for the administration of an intravenous versus subcutaneous therapy: in non-Hodgkin’s lymphoma and in breast cancer
Table 4 Impact of intravenous versus subcutaneous administration from an FTEs perspective: in non-Hodgkin’s lymphoma and in breast cancer
Table 5 Wastage calculation between intravenous and subcutaneous administration in non-Hodgkin’s lymphoma (rituximab) and in breast cancer (trastuzumab)